Singapore Clinical Trial: A Phase 1, Investigator- and Participant-Blinded, Placebo-Controlled, Randomized, Multiple-Dose Study to Evaluate the Gastric Emptying Delay, Pharmacokinetics, Safety, and Tolerability of Eloralintide in Participants with Obesity or Overweight

Singapore, Oct. 3 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Investigator- and Participant-Blinded, Placebo-Controlled, Randomized, Multiple-Dose Stu... Read More

Clinical Trial: Artificial Intelligence-assisted Primary Care for RSV Prevention (AIPC-RSV) in China

U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07856290) titled 'Artificial Intelligence-assisted Primary Care for RSV Prevention (AIPC-RSV) in China' on Sep... Read More

Singapore Clinical Trial: A Phase 1, Investigator- and Participant-Blinded, Placebo-Controlled, Randomized, Multiple-Dose Study to Evaluate the Gastric Emptying Delay, Pharmacokinetics, Safety, and Tolerability of Eloralintide in Participants with Obesity or Overweight

Singapore, Oct. 3 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Investigator- and Participant-Blinded, Placebo-Controlled, Randomized, Multiple-Dose Stu... Read More

Singapore Clinical Trial: A Phase 1 randomized, double-blind, placebo-controlled, single-ascending-dose study investigating the safety and tolerability of ARD001 in healthy adult subjects and a Phase 2 open-label, multiple-dose study in adult subjects with hemophilia A

Singapore, Oct. 3 -- The Health Sciences Authority received information related to the study titled 'A Phase 1 randomized, double-blind, placebo-controlled, single-ascending-dose study investigating t... Read More

Clinical Trial: Prediction Of Lymphedema In Patients With Inflammatory BreastCancer Using Preoperative Bioimpedance Measurements

U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07855627) titled 'Prediction Of Lymphedema In Patients With Inflammatory BreastCancer Using Preoperative Bioim... Read More

Singapore Clinical Trial: A Multinational, Multicenter Study With an Open-Label Phase 1b and a Randomized, Double-Blind, Placebo-Controlled Phase 3 Followed by an Open-Label Extension to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Radiprodil in Participants With GRIN-Related Neurodevelopmental Disorder

Singapore, Oct. 3 -- The Health Sciences Authority received information related to the study titled 'A Multinational, Multicenter Study With an Open-Label Phase 1b and a Randomized, Double-Blind, Plac... Read More

Singapore Clinical Trial: A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Solution for Injection (TLX101-Tx) Plus Lomustine Versus Lomustine Alone in Patients with Radiographically Confirmed Recurrent Glioblastoma at First Recurrence (IPAX-3)

Singapore, Oct. 3 -- The Health Sciences Authority received information related to the study titled 'A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Soluti... Read More

Singapore Clinical Trial: RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma

Singapore, Oct. 3 -- The Health Sciences Authority received information related to the study titled 'RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Mo... Read More

Clinical Trial: Interaction Between White Potato Consumption and Meal Timing on Glycemic Response and Appetite in Adults [Experiment 2]

U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07854938) titled 'Interaction Between White Potato Consumption and Meal Timing on Glycemic Response and Appeti... Read More

Singapore Clinical Trial: A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors, including Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors

Singapore, Oct. 3 -- The Health Sciences Authority received information related to the study titled 'A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembro... Read More

• ««
• «
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• »
• »»